Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Add To Watchlist

Recent & Breaking News (NDAQ:NKTR)

Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics

PR Newswire June 23, 2016

Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

PR Newswire June 6, 2016

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City

PR Newswire June 2, 2016

Nektar Therapeutics Announces Executive Management Promotions

PR Newswire June 2, 2016

Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD™ (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases

PR Newswire June 1, 2016

Nektar Therapeutics Reports Financial Results for the First Quarter of 2016

PR Newswire May 3, 2016

Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets

PR Newswire April 28, 2016

Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration

PR Newswire April 18, 2016

Nektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA

PR Newswire March 3, 2016

Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results

PR Newswire March 1, 2016

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets

PR Newswire February 26, 2016

Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research

PR Newswire February 1, 2016

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire January 6, 2016

Identifying Opportunity, Placing Risk -- Analyst Notes on Cara Therapeutics, Sigma Designs, Pep Boys - Manny Moe and Jack and Nektar Therapeutics

Accesswire December 21, 2015

Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age

Business Wire December 21, 2015

A Change in Tides - Complementary Research on Nektar, California Resources, Zynga and Finisar

Accesswire December 10, 2015

Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York

PR Newswire December 8, 2015

Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

PR Newswire December 8, 2015

Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London

PR Newswire November 17, 2015

Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds

PR Newswire November 16, 2015